Jesús San Miguel, MD, Professor of Medicine (Hematology), Head of the Hematology Department at the University Hospital of Salamanca, and Director of the Biomedical Research Institute of Salamanca, Spain, was awarded the José Carreras Lecture at the 17th Congress of the European Hematology Association (EHA) held recently in Amsterdam. He presented his lecture during the meeting’s opening ceremony.
Seminal Contributions
A leader in the area of multiple myeloma, Dr. San Miguel has made seminal contributions to myeloma cell biology. These included studies of the diagnostic and prognostic roles of immunophenotyping, morphology, and molecular genetics together with investigation of disease evolution and the significance of minimal residual disease. In addition, in the area of therapeutics he has made major contributions to pivotal preclinical and clinical studies of new antimyeloma drugs including proteasome inhibitors and chromatin-modifying agents.
Dr. San Miguel has provided international leadership through the generation of numerous guidelines on diagnosis, classification, and treatment and was responsible for the creation of the International Staging System for multiple myeloma. ■
